|
|
|||||||
Acute Lymphoblastic Leukemia |
From the St. Anna Childrens Hospital (LK, AA, HG, OAH, MND, GM); Childrens Cancer Research Institute, Vienna, Austria (TL, MK, SS, HG); Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany (MS)
Correspondence: Georg Mann, MD, Department of Hematology and Oncology, St. Anna Childrens Hospital, Kinderspitalgasse 6, A-1090 Vienna, Austria. E-mail: georg.mann{at}stanna.at
Lessons from the analysis of children with TCF3-PBX1 ALL could help to identify treatment components essential for this leukemia subtype. Of 859 children with ALL who were treated in ALL-BFM trials in Austria, 31 (3.6%) had a TCF3-PBX1 ALL. The 5-year event-free survival rate for these 31 patients was 90%±5%. Patients with TCF3-PBX1 ALL treated on the ALL-BFM 86 trial had a poorer outcome than patients with TCF3-PBX1 ALL treated on later trials. These data document that contemporary ALL-BFM treatment is highly effective in children with TCF3-PBX1 ALL. Implementation of early dose-intensified remission induction may be an essential treatment component.
Key words: outcome, TCF3-PBX1, acute lymphoblastic leukemia.
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |